Reiss Kim A, Soares Kevin C, Torphy Robert J, Gyawali Bishal
Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473204. doi: 10.1200/EDBK-25-473204. Epub 2025 Apr 2.
Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms of incidence but sixth for mortality signifying its aggressive behavior and limited treatment options. While the mortality rates for many other solid tumors have substantially improved over the past few decades, temporal trends in pancreatic cancer mortality rates are quite sobering. In the United States, from 2000 to 2020, the mortality rates from pancreatic cancer have increased, whereas at the same time, mortality rates from other cancers, such as lung, colorectal, or kidney, have fallen appreciably. Is this for lack of treatment innovation? How do we improve survival for patients with pancreatic cancer? In this chapter, we discuss the recent advances and future directions with targeted therapies and immunotherapies in the treatment of pancreatic cancer, and provide the reasons for both optimism and caution for the future of systemic treatment of pancreatic cancer.
胰腺腺癌仍然是最具侵袭性且最难治疗的实体瘤恶性肿瘤之一，其死亡率与发病率之比很高。在全球范围内，胰腺癌的发病率排名第12，但死亡率排名第6，这表明其侵袭性强且治疗选择有限。虽然在过去几十年中，许多其他实体瘤的死亡率有了显著改善，但胰腺癌死亡率的时间趋势却相当严峻。在美国，从2000年到2020年，胰腺癌的死亡率有所上升，而与此同时，其他癌症（如肺癌、结直肠癌或肾癌）的死亡率则明显下降。这是因为缺乏治疗创新吗？我们如何提高胰腺癌患者的生存率？在本章中，我们将讨论胰腺癌治疗中靶向治疗和免疫治疗的最新进展及未来方向，并为胰腺癌全身治疗的未来提供乐观和谨慎的理由。
